07:00 , Oct 19, 2015 |  BC Week In Review  |  Company News

Inhibrx, Alpha-1 Foundation deal

Inhibrx and Alpha-1’s Alpha-1 Project Inc. subsidiary partnered to develop a recombinant alpha-1 antitrypsin (AAT) therapeutic. Alpha-1 will make an undisclosed equity investment in Inhibrx, which is developing AAT-Fc. The recombinant AAT (...